- Study procedure:

- Umbralisib 800mg PO once daily

- Inclusion: confirmed diagnosis ofCLL,d/c of prior BTK inhibitor or PI3K delta inhibitor,

presence of measurable disease, no disease progression 14 days following prior KI

discontinuation, ≥18 years old, ECOG ≤2, adequate bone marrow and organ function